The estimated Net Worth of Cato T Laurencin is at least 132 千$ dollars as of 29 June 2024. Cato Laurencin owns over 6,104 units of MiMedx Inc stock worth over 131,680$ and over the last 4 years Cato sold MDXG stock worth over 0$.
Cato has made over 7 trades of the MiMedx Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently Cato exercised 6,104 units of MDXG stock worth 37,784$ on 29 June 2024.
The largest trade Cato's ever made was exercising 8,242 units of MiMedx Inc stock on 8 December 2022 worth over 51,018$. On average, Cato trades about 2,037 units every 36 days since 2020. As of 29 June 2024 Cato still owns at least 21,273 units of MiMedx Inc stock.
You can see the complete history of Cato Laurencin stock trades at the bottom of the page.
Cato's mailing address filed with the SEC is 1775, West Oak Commons Court Northeast, Marietta, Cobb, Georgia, 30062, United States.
Over the last 15 years, insiders at MiMedx Inc have traded over 15,165,698$ worth of MiMedx Inc stock and bought 1,553,718 units worth 4,191,559$ . The most active insiders traders include Fund Management Ltd.Okumus ...、Steve Gorlin、Parker H Petit. On average, MiMedx Inc executives and independent directors trade stock every 48 days with the average trade being worth of 487,865$. The most recent stock trade was executed by William Frank Iv Hulse on 13 March 2024, trading 20,381 units of MDXG stock currently worth 162,029$.
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and burns; AmnioFix, a semi-permeable protective barrier membrane product for the treatment of wounds related to surgical procedures; EpiCord and AmnioCord that are dehydrated human umbilical cord allografts intended for homologous applications; and AmnioFill that consists of particles of connective tissue matrix derived from placental disc and placental membranes. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
MiMedx Inc executives and other stock owners filed with the SEC include: